

University of Groningen

## Clinical pharmacology and therapeutic drug monitoring of voriconazole

Veringa, Anette

**IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.**

*Document Version*

Publisher's PDF, also known as Version of record

*Publication date:*

2019

[Link to publication in University of Groningen/UMCG research database](#)

*Citation for published version (APA):*

Veringa, A. (2019). *Clinical pharmacology and therapeutic drug monitoring of voriconazole*. Rijksuniversiteit Groningen.

### Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

### Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

*Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.*

## List of publications

**Veringa A**, Sturkenboom MGG, Dekkers BGJ, Koster RA, Roberts JA, Peloquin CA, Touw DJ, Alffenaar JWC. LC-MS/MS for Therapeutic Drug Monitoring of anti-infective drugs. *Trac – Trends in analytical chemistry*, 84 (2016) 34-40. DOI:10.1016/j.trac.2015.11.026.

Huurneman LJ, Neely M, **Veringa A**, Docobo Pérez F, Ramos-Martin V, Tissing WJ, Alffenaar JW, Hope W. Pharmacodynamics of voriconazole in children: further steps along the path to true individualized therapy. *Antimicrob Agent Chemother*, 2016 March 25;60(4). DOI: 10.1128/AAC.03023-15

Dekkers BG, Bakker M, van der Elst KC, Sturkenboom MG, **Veringa A**, Span LF, Alffenaar JC. Therapeutic drug monitoring of posaconazole: an update. *Curr Fungal Infect Rep*, 2016;10:51-61. DOI: 10.1007/s12281-016-0255-4.

**Veringa A**, Ter Avest M, Touw DJ, Alffenaar JC. Comment on: utility of voriconazole therapeutic drug monitoring: a meta-analysis. *J Antimicrob Chemother*, 2016 Nov; 71(11):3316-3317.

**Veringa A**, Ter Avest M, Span LF, van den Heuvel ER, Touw DJ, Zijlstra JG, Kosterink JG, van der Werf TS, Alffenaar JC. Voriconazole metabolism is influenced by severe inflammation: a prospective study. *J Antimicrob Chemother*, 2017 Jan; 72(1):261-267.

**Veringa A**, van der Elst KC, Day JN, Thwaites GE, Alffenaar JW. Sertraline for HIV-associated cryptococcal meningitis. *Lancet Infect Dis*, 2016 Oct; 16(10):1111. DOI: 10.1016/S1473-3099(16)30321-8.

**Veringa A**, Geling S, Span LFR, Vermeulen KM, Zijlstra JG, van der Werf TS, Kosterink JGW, Alffenaar JWC. Bioavailability of voriconazole in hospitalized patients. *Int J Antimicrob Agents*, 2017 Feb;49(2):243-246. DOI: 10.1016/j.ijantimicag.2016.10.010

Ter Avest M, **Veringa A**, van den Heuvel ER, Kosterink JGW, Schölvinck EH, Tissing WJE, Alffenaar JWC. The effect of inflammation on voriconazole trough concentrations in children. *Br J Clin Pharmacol*, 2017 Mar;83(3):678-680. DOI: 10.1111/bcp.13151.

Van der Elst KC, **Veringa A**, Zijlstra JG, Beishuizen A, Klont R, Brummelhuis-Visser P, Uges DR, Touw DJ, Kosterink JG, van der Werf TS, Alffenaar JC. Low caspofungin exposure in patients in the intensive care unit. *Antimicrob Agents Chemother*, 2017 Jan 24;61(2). pii: e01582-16. doi: 10.1128/AAC.01582-16.

Boonstra JM, van der Elst KC, **Veringa A**, Jongedijk EM, Brüggemann RJ, Koster RA, Kampinga GA, Kosterink JG, van der Werf TS, Zijlstra JG, Touw DJ, Alffenaar JWC. Pharmacokinetic Properties of Micafungin in Critically Ill Patients Diagnosed with Invasive Candidiasis. *Antimicrob Agents Chemother*, 2017 Nov 14, pii: AAC.01582-16.

Dekkers BGJ, **Veringa A**, Marriott DJE, Boonstra JM, van der Elst KCM, Doukas FF, McLachlan AJ, Alffenaar JC. Invasive Candidiasis in the Elderly: Considerations for Drug Therapy. *Drugs Aging*, 2018 Sep; 35(9): p. 781-789. doi: 10.1007/s40266-018-0576-9.

Märtson AG, **Veringa A**, Bakker M, van den Heuvel ER, Touw DJ, van der Werf TS, Span LFR, C Alffenaar JW. Posaconazole trough concentrations are not influenced by inflammation: A prospective study. *Int J Antimicrob Agents*, 2019 Jan 11. pii: S0924-8579(19)30006-8. doi: 10.1016/j.ijantimicag.2019.01.006.